Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView’s Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don’t miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.
View all episodes
